|
1
|
Maleczek M, Reszeć-Giełażyn J, Szymulewska-Konopko K. Beneficial Effects of Selenium and Its Supplementation on Carcinogenesis and the Use of Nanoselenium in the Treatment of Malignant Tumors. Int J Mol Sci 2024; 25:11285. [PMID: 39457066 PMCID: PMC11508626 DOI: 10.3390/ijms252011285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2024] [Revised: 10/09/2024] [Accepted: 10/12/2024] [Indexed: 10/28/2024] Open
Abstract
Selenium was recognized as a non-toxic element in the second half of the 20th century. Since then, the positive impact of selenium on the functioning of the human body has been noticed. It has been shown that low levels of selenium in the body are significantly associated with a higher risk of developing cancer. Selenium acts as an antioxidant and inhibits the proliferation of cancer cells. It has been shown that selenium supplementation may contribute to reducing the risk of DNA mutations and carcinogenesis. Nanomedicine has become very helpful in both the diagnosis and treatment of cancer. Due to its anticancer properties, selenium is used in nanotechnology as selenium nanoparticles.
Collapse
Affiliation(s)
| | - Joanna Reszeć-Giełażyn
- Department of Medical Pathomorphology, Medical University of Białystok, 15-269 Białystok, Poland; (M.M.)
| | | |
Collapse
|
|
2
|
Qi L, Wang Y, Wang R, Wang M, Jablonska E, Zhou H, Su S, Jia Y, Zhang Y, Li Q, Wang T. Association of Plasma Selenium and Its Untargeted Metabolomic Profiling with Cervical Cancer Prognosis. Biol Trace Elem Res 2023; 201:4637-4648. [PMID: 36609649 DOI: 10.1007/s12011-022-03552-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 12/29/2022] [Indexed: 01/08/2023]
Abstract
Selenium is an essential trace element that shows beneficial or adverse health effects depending on the dose. However, its role in the prognosis of cervical cancer (CC) has been less reported. We aimed to explore the association between selenium status and prognosis in CC patients with different prognoses and to elucidate the underlying mechanism of selenium in CC prognosis. This cross-sectional observational study had a case-control design at the Harbin Medical University Cancer Hospital and was conducted using 29 CC cases with poor prognosis and 29 CC cases with good prognosis. Plasma selenium levels were measured using an atomic fluorescence spectrometer. Untargeted metabolomics was used to identify metabolites. Plasma selenium levels of the poor prognosis group (49.90 ± 13.81 µg/L) were lower than that of the good prognosis group (59.38 ± 13.00 µg/L, t = 2.69, P = 0.009). In the logistic regression analysis, plasma selenium levels were associated with lower poor prognosis risk [odds ratio (OR) = 0.952, 95% CI: 0.909-0.998]. Receiver operating characteristic curve analysis revealed an optimal cut-off point of plasma selenium levels ≤ 47.68 µg/L for poor prognosis of CC. Based on the cut-off selenium levels, patients with different prognoses were divided into high and low selenium groups. Metabolomic analysis revealed six differential metabolites among different prognoses with low and high selenium levels, and the glycerophospholipid (GPL) metabolism was enriched. Plasma selenium levels were positively correlated with metabolite levels. Our findings provided evidence that low plasma selenium levels may associate with a poor prognosis of CC. Low plasma selenium levels might suppress GPL metabolism and influence the prognosis of CC. This finding requires confirmation in future prospective cohort studies.
Collapse
Affiliation(s)
- Lei Qi
- Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China
- School of Public Health, Qiqihar Medical University, Qiqihar, 161006, Heilongjiang, China
| | - Yuanyuan Wang
- Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China
| | - Ruixiang Wang
- Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China
| | - Mingxing Wang
- Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China
| | - Ewa Jablonska
- Department of Translational Research, Nofer Institute of Occupational Medicine, Sw. Teresy 8 Street, 91-348, Lodz, Poland
| | - Huihui Zhou
- Department of Public Health, Jining Medical University, Jining, 272029, China
| | - Shengqi Su
- Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China
| | - Yuehui Jia
- Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China
| | - Yiyi Zhang
- Yantai Center for Disease Control and Prevention, No.17 Fuhou Road, Laishan District, Yantai, 264003, China
| | - Qi Li
- Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
| | - Tong Wang
- Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China.
| |
Collapse
|
|
3
|
Frydrych A, Krośniak M, Jurowski K. The Role of Chosen Essential Elements (Zn, Cu, Se, Fe, Mn) in Food for Special Medical Purposes (FSMPs) Dedicated to Oncology Patients-Critical Review: State-of-the-Art. Nutrients 2023; 15:1012. [PMID: 36839370 PMCID: PMC9961387 DOI: 10.3390/nu15041012] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 02/10/2023] [Accepted: 02/12/2023] [Indexed: 02/22/2023] Open
Abstract
The scoping review aimed to characterise the role of selected essential elements (Zn, Cu, Se, Fe, Mn) in food for special medical purposes (FSMPs) aimed at oncology patients. The scope review was conducted using Scopus, Google Scholar, and Web of Science to find published references on this subject. Data from the reviewed literature were related to the physiological functions of the element in the body, and the effects of deficiencies and excesses, referring to the latest ESPEN and EFSA guidelines, among others. Important dietary indices/parameters based on the literature review are provided for each element. On the basis of the literature, data on the level of elements in patients with cancer were collected. The content of these elements in 100 mL of FSMPs was read from the manufacturers' declarations. The literature has been provided on the importance of each element in cancer. Our findings show that the essential elements (Zn, Cu, Se, Fe, and Mn) of FSMPs for cancer patients are not adequately treated. We suggest solutions to ensure the safe use of FSMPs in oncology patients.
Collapse
Affiliation(s)
- Adrian Frydrych
- Laboratory of Innovative Toxicological Research and Analyses, Institute of Medical Studies, Medical College, Rzeszów University, Aleja Majora W. Kopisto 2a, 35-959 Rzeszow, Poland
| | - Mirosław Krośniak
- Department of Food Chemistry and Nutrition, Medical College, Jagiellonian University, Medyczna 9, 30-688 Kraków, Poland
| | - Kamil Jurowski
- Laboratory of Innovative Toxicological Research and Analyses, Institute of Medical Studies, Medical College, Rzeszów University, Aleja Majora W. Kopisto 2a, 35-959 Rzeszow, Poland
- Department of Regulatory and Forensic Toxicology, Institute of Medical Expertises, Aleksandrowska 67/93, 91-205 Łódź, Poland
| |
Collapse
|
|
4
|
Rogoża-Janiszewska E, Malińska K, Baszuk P, Marciniak W, Derkacz R, Lener M, Jakubowska A, Cybulski C, Huzarski T, Masojć B, Gronwald J, Rudnicka H, Kram A, Kiedrowicz M, Boer M, Dębniak T, Lubiński J. Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines 2021; 9:biomedicines9080991. [PMID: 34440195 PMCID: PMC8392027 DOI: 10.3390/biomedicines9080991] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 08/03/2021] [Accepted: 08/05/2021] [Indexed: 11/16/2022] Open
Abstract
Melanoma is one of the most aggressive human malignancies. The determination of prognostic biomarkers is important for the early detection of recurrence and for the enrollment of the patients into different treatment regimens. Herein, we report the 10-year survival of 375 melanoma patients depending on their serum selenium levels. The study group was followed up from the date of melanoma diagnosis until death or 2020. Patients were assigned to one of four categories, in accordance with the increasing selenium level (I-IV quartiles). The subgroup with low selenium levels had a significant lower survival rate in relation to patients with high selenium levels, HR = 8.42; p = 0.005 and HR = 5.83; p = 0.02, for uni- and multivariable models, respectively. In the univariable analysis, we also confirmed the association between Breslow thickness, Clark classification and age at melanoma prognosis. In conclusion, a low serum selenium level was associated with an increased mortality rate in the 10 years following melanoma diagnosis. Future studies in other geographic regions with low soil selenium levels should be conducted to confirm our findings.
Collapse
Affiliation(s)
- Emilia Rogoża-Janiszewska
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
- Correspondence:
| | - Karolina Malińska
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Piotr Baszuk
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Wojciech Marciniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Róża Derkacz
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Marcin Lener
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Anna Jakubowska
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Cezary Cybulski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Tomasz Huzarski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Bartłomiej Masojć
- Radiation Oncology Department, West Pomeranian Oncology Center, 71-730 Szczecin, Poland;
| | - Jacek Gronwald
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Helena Rudnicka
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Andrzej Kram
- Pathology Department, West Pomeranian Oncology Center, 71-730 Szczecin, Poland;
| | - Magdalena Kiedrowicz
- Department of Skin Diseases and Venerology, Pomeranian Medical University in Szczecin, 72-010 Police, Poland; (M.K.); (M.B.)
| | - Magdalena Boer
- Department of Skin Diseases and Venerology, Pomeranian Medical University in Szczecin, 72-010 Police, Poland; (M.K.); (M.B.)
| | - Tadeusz Dębniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| | - Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland; (K.M.); (P.B.); (W.M.); (R.D.); (M.L.); (A.J.); (C.C.); (T.H.); (J.G.); (H.R.); (T.D.); (J.L.)
| |
Collapse
|
|
5
|
ATABEY S, YILDIZTEKİN M, TUNA AL, NAZLI O, CEYLAN O, YOKAŞ İ. Mineral Nutrition Status of Some Aromatic Plants Grown in Muğla, Determination of Their Soil Characteristics and Uses in the Kitchen. INTERNATIONAL JOURNAL OF SECONDARY METABOLITE 2020. [DOI: 10.21448/ijsm.753739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
|
6
|
Lewandowska M, Sajdak S, Lubiński J. Serum Selenium Level in Early Healthy Pregnancy as a Risk Marker of Pregnancy Induced Hypertension. Nutrients 2019; 11:nu11051028. [PMID: 31071931 PMCID: PMC6566672 DOI: 10.3390/nu11051028] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 04/30/2019] [Accepted: 05/01/2019] [Indexed: 01/06/2023] Open
Abstract
Selenium (Se) is an antioxidant nutrient whose deficiency can influence adverse outcomes of pregnancy. The aim of this study is to determine whether serum Se level in early healthy pregnancy may be a risk marker for pregnancy induced hypertension. We obtained data from our prospective study in which we recruited healthy women in weeks 10–14 of a single pregnancy. In this analysis, we examined 121 women who subsequently developed pregnancy-induced hypertension and matched 363 women who remained normotensive. We measured Se levels (using the ICP-MS technique) in the serum in weeks 10–14 of the pregnancy. The odds ratios of pregnancy-induced hypertension (95% confidence intervals) were calculated using multivariate logistic regression. We found that the mean Se level was lower in the case group compared to the control (57.51 vs. 62.89 μg/L; p = 2.6 × 10−10). Excessive body mass index (BMI) and smoking influenced the estimated odds ratios. In the subgroup of women who had never smoked with normal pre-pregnancy BMI, the adjusted odds ratio (AOR) of pregnancy-induced hypertension was 15.34 (95% CI: 2.73–86.31, p = 0.002) for Se levels in the lowest quartile (≤57.68 µg/L), as compared to the highest quartile (>66.60 µg/L), after adjusting for all the accepted confounders. In the whole cohort, the prognostic value of Se by logistic regression showed that the area under curve (AUC) = 0.814. In our study, one can consider the role of Se as a risk marker of pregnancy-induced hypertension.
Collapse
Affiliation(s)
- Małgorzata Lewandowska
- Division of Gynecological Surgery, Poznań University of Medical Sciences, 60-535 Poznań, Poland.
| | - Stefan Sajdak
- Division of Gynecological Surgery, Poznań University of Medical Sciences, 60-535 Poznań, Poland.
| | - Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland.
| |
Collapse
|